Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis

Journal of Infection in Developing Countries

Volumn 7, Issue 3, 2013, Pages 169-181

  Morandi, Matteo ^a   Sali, Michela ^a   Manganelli, Riccardo ^b   Delogu, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

BCG; Cell wall; HBHA; Tuberculosis; Vaccine

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; CELL MEMBRANE PROTEIN; HEMAGGLUTININ; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LISTERIOLYSIN O; LIVE VACCINE; PHOP PROTEIN; PROTEIN P19; TUMOR NECROSIS FACTOR;

BACTERIAL CELL WALL; BACTERIAL VIRULENCE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; LISTERIA MONOCYTOGENES; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TUBERCULOSIS;

BACTERIAL PROTEINS; CELL WALL; HUMANS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84875184892     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.3114     Document Type: Review

References (100)

1. Gagneux S (2012) Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci 367: 850-859.
2. World Health Organization (2011) Global Tuberculosis Control. Surveillance, Planning, Financing. (www.who.int/tb/publications/global_report/en/).
3. Cegielski JP (2010) Extensively drug-resistant tuberculosis: "there must be some kind of way out of here". Clin Infect Dis 50 Suppl 3: S195-S200.
4. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54: 579-581.
5. Brennan MJ, Fruth U, Milstien J, Tiernan R, de Andrade NS, Chocarro L (2007) Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 4: e252.
6. Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
7. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, and Fineberg HV (1995) The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96: 29-35.
8. Kaufmann SH (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33: 567-577.
9. Sali M, Clarizio S, Pusceddu C, Zumbo A, Pecorini G, Rocca S, Zanetti S, Delogu G, and Fadda G (2008) Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs. Microbes Infect 10: 605-612.
10. Weinrich Olsen A, van Pinxteren LA, Meng OL, Birk RP, and Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69: 2773-2778.
11. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, and Andersen P (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17: 189-194.
12. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, Chen B, Chan J, Braunstein M, Orme IM, Derrick SC, Morris SL, Jacobs WR Jr, Porcelli SA (2007) Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117: 2279-2288.
13. Sambandamurthy VK and Jacobs WR, Jr (2005) Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7: 955-961.
14. Brennan MJ (2005) The tuberculosis vaccine challenge. Tuberculosis (Edinb.) 85: 7-12.
15. Horwitz MA, Harth G, Dillon BJ, and Maslesa-Galic' S (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97: 13853-13858.
16. Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR, Jr, and Bloom BR (2000) Attenuation of and protection induced by a leucine auxotroph of mycobacterium tuberculosis [In Process Citation]. Infect Immun 68: 2888-2898.
17. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B (2006) The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24: 3408-3419.
18. Gioffre A, Infante E, Aguilar D, Santangelo MP, Klepp L, Amadio A, Meikle V, Etchechoury I, Romano MI, Cataldi A, Hernàndez RP, Bigi F (2005) Mutation in mce operons attenuates Mycobacterium tuberculosis virulence. Microbes Infect 7: 325-334.
19. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, and Horwitz MA (2008) A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198: 1491-1501.
20. Horwitz MA and Harth G (2003) A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71: 1672-1679.
21. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, and Kaufmann SH (1998) Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 95: 5299-5304.
22. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser EA, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
23. Grode L, Kursar M, Fensterle J, Kaufmann SH, and Hess J (2002) Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J Immunol 168: 1869-1876.
24. Kaufmann SH and Gengenbacher M (2012) Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 23: 900-907
25. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga G, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC (2009) Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27: 4412-4423.
26. Russell DG (2007) Who puts the tubercle in tuberculosis? Nat Rev Microbiol 5: 39-47.
27. Kaufmann SH, Cole ST, Mizrahi V, Rubin E, and Nathan C (2005) Mycobacterium tuberculosis and the host response. J Exp Med 201: 1693-1697.
28. Flynn JL and Chan J (2005) What's good for the host is good for the bug. Trends Microbiol 13: 98-102.
29. Abdallah AM, Gey van Pittius NC, Champion PA, Cox J, Luirink J, Vandenbroucke-Grauls CM, Appelmelk BJ, and Bitter W (2007) Type VII secretion--mycobacteria show the way. Nat Rev Microbiol 5: 883-891.
30. Stoop EJ, Bitter W, and van der Sar AM (2012) Tubercle bacilli rely on a type VII army for pathogenicity. Trends Microbiol 20: 477-484.
31. Sutcliffe IC and Harrington DJ (2004) Lipoproteins of Mycobacterium tuberculosis: an abundant and functionally diverse class of cell envelope components. FEMS Microbiol Rev 28: 645-659.
32. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, III, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Sulston JE, Taylor K, Whitehead S, Barrell BG (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence [see comments] [published erratum appears in Nature 1998 Nov 12;396(6707):190] Nature 393: 537-544.
33. Wilkinson KA, Newton SM, Stewart GR, Martineau AR, Patel J, Sullivan SM, Herrmann JL, Neyrolles O, Young DB, and Wilkinson RJ (2009) Genetic determination of the effect of post-translational modification on the innate immune response to the 19 kDa lipoprotein of Mycobacterium tuberculosis. BMC Microbiol 9: 93.
34. Booth RJ, Williams DL, Moudgil KD, Noonan LC, Grandison PM, McKee JJ, Prestidge RL, and Watson JD (1993) Homologs of Mycobacterium leprae 18-kilodalton and Mycobacterium tuberculosis 19-kilodalton antigens in other mycobacteria. Infect Immun 61: 1509-1515.
35. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, Brennan PJ, Bloom BR, Godowski PJ, Modlin RL (1999) Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285: 732-736.
36. Pai RK, Convery M, Hamilton TA, Boom WH, and Harding CV (2003) Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol 171: 175-184.
37. Lopez M, Sly LM, Luu Y, Young D, Cooper H, and Reiner NE (2003) The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2. J Immunol 170: 2409-2416.
38. Ciaramella A, Cavone A, Santucci MB, Garg SK, Sanarico N, Bocchino M, Galati D, Martino A, Auricchio G, D'Orazio M, Stewart GR, Neyrolles O, Young DB, Colizzi V, Fraziano M (2004) Induction of apoptosis and release of interleukin-1 beta by cell wall-associated 19-kDa lipoprotein during the course of mycobacterial infection. J Infect Dis 190: 1167-1176.
39. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, Gan HX, Divangahi M, and Remold HG (2011) Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol 4: 279-287.
40. Yeremeev VV, Lyadova IV, Nikonenko BV, Apt AS, Abou-Zeid C, Inwald J, and Young DB (2000) The 19-kD antigen and protective immunity in a murine model of tuberculosis [In Process Citation]. Clin Exp Immunol 120: 274-279.
41. Yeremeev VV, Stewart GR, Neyrolles O, Skrabal K, Avdienko VG, Apt AS, and Young DB (2000) Deletion of the 19kDa antigen does not alter the protective efficacy of BCG. Tuber Lung Dis 80: 243-247.
42. Henao-Tamayo M, Junqueira-Kipnis AP, Ordway D, Gonzales-Juarrero M, Stewart GR, Young DB, Wilkinson RJ, Basaraba RJ, and Orme IM (2007) A mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo but retains potent vaccinogenic properties. Vaccine 25: 7153-7159.
43. Santucci MB, Amicosante M, Cicconi R, Montesano C, Casarini M, Giosue S, Bisetti A, Colizzi V, and Fraziano M (2000) Mycobacterium tuberculosis-induced apoptosis in monocytes/macrophages: early membrane modifications and intracellular mycobacterial viability. J Infect Dis 181: 1506-1509.
44. Menozzi FD, Rouse JH, Alavi M, Laude-Sharp M, Muller J, Bischoff R, Brennan M., and Locht C (1996) Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184: 993-1001.
45. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, and Menozzi FD (2001) The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412: 190-194.
46. Menozzi FD, Bischoff R, Fort E, Brennan MJ, and Locht C (1998) Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci USA 95: 12625-12630.
47. Delogu G and Brennan MJ (1999) Functional domains present in the mycobacterial hemagglutinin, HBHA. J Bacteriol 181: 7464-7469.
48. Esposito C, Marasco D, Delogu G, Pedone E, and Berisio R (2011) Heparin-binding hemagglutinin HBHA from Mycobacterium tuberculosis affects actin polymerisation. Biochem Biophys Res Commun 410: 339-344.
49. Delogu G, Fadda G, and Brennan MJ (2012) Impact of Structural Domains of the Heparin Binding Hemagglutinin of Mycobacterium tuberculosis on Function. Protein Pept Lett 19: 1035-1039.
50. Dupres V, Menozzi FD, Locht C, Clare BH, Abbott NL, Cuenot S, Bompard C, Raze D, and Dufrene YF (2005) Nanoscale mapping and functional analysis of individual adhesins on living bacteria. Nature Methods 2: 515-520.
51. Li Z, Howard A, Kelley C, Delogu G, Collins F, and Morris S (1999) Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences [In Process Citation]. Infect Immun 67: 4780-4786.
52. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, Menozzi FD, Locht C, and Mascart F (2002) Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 185: 513-520.
53. Zanetti S, Bua A, Delogu G, Pusceddu C, Mura M, Saba F, Pirina P, Garzelli C, Vertuccio C, Sechi LA, and Fadda G (2005) Patients with pulmonary tuberculosis develop a strong humoral response against methylated heparin-binding hemagglutinin. Clin Diagn Lab Immunol 12: 1135-1138.
54. Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, Pickett T, Drowart A, Debrie AS, Delogu G, Menozzi FD, Sergheraert C, Brennan MJ, Mascart F, and Locht C (2004) Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10: 935-941.
55. Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, Locht C, and Brennan MJ (2004). The Mycobacterial Heparin-binding Hemagglutinin is a Protective antigen in the Mouse Aerosol Challenge Model of Tuberculosis. Infect Immun 72: 6799-6805.
56. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verscheure V, Debrie AS, Doherty TM, Van Vooren JP, Locht C, Mascart F (2007) Heparin-Binding-Hemagglutinin-Induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS ONE 2: e926.
57. Place S, Verscheure V, de SN, Hougardy JM, Schepers K, Dirix V, Dediste A, Michel O, Drowart A, Allard SD, Doherty TM, Lecher S, Locht C, Mascart F (2010) Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humans. Am J Respir Crit Care Med 182: 848-854.
58. Shin AR, Lee KS, Lee JS, Kim SY, Song CH, Jung SB, Yang CS, Jo EK, Park JK, Paik TH, Kim HJ (2006) Mycobacterium tuberculosis HBHA protein reacts strongly with the serum immunoglobulin M of tuberculosis patients. Clin Vaccine Immunol 13: 869-875.
59. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua A, Molicotti P, Zanetti S, Lauria FN, Grisetti S, Magnavita N, Fadda G, Girardi E, and Goletti D (2011) Methylated HBHA produced in M. smegmatis Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. PLoS ONE 6: e1815.
60. Molicotti P, Bua A, Cubeddu M, Cannas S, Delogu G, and Zanetti S (2011) Tuberculosis patients are characterized by a low-IFN-gamma/high-TNF-alpha response to methylated HBHA produced in M. smegmatis. Diagn Microbiol Infect Dis 71: 449-452.
61. Corbiere V, Pottier G, Bonkain F, Schepers K, Verscheure V, Lecher S, Doherty TM, Locht C, and Mascart F (2012) Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS ONE 7: e43285.
62. Temmerman ST, Place S, Debrie AS, Locht C, and Mascart F (2005) Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J Infect Dis 192: 226-232.
63. Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, Matsuzaki G, and Arakawa T (2008) Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine 26: 924-932.
64. Zhao S, Zhao Y, Mao F, Zhang C, Bai B, Zhang H, Shi C, and Xu Z (2012) Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS ONE 7: e31908.
65. Balasubramanian V, Wiegeshaus EH, Taylor BT, and Smith DW (1994) Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 75: 168-178.
66. Bottai D, Di LM, Majlessi L, Frigui W, Simeone R, Sayes F, Bitter W, Brennan MJ, Leclerc C, Batoni G, Campa M, Brosch R, Esin S (2012). Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Mol Microbiol 83: 1195-1209
67. Gey van Pittius NC, Sampson SL, Lee H, Kim Y, van Helden PD, and Warren RM (2006) Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 6: 95.
68. Gey van Pittius NC, Gamieldien J, Hide W, Brown GD, Siezen RJ, and Beyers AD (2001) The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol 2: RESEARCH0044.
69. Gordon SV, Eiglmeier K, Garnier T, Brosch R, Parkhill J, Barrell B, Cole ST, and Hewinson RG (2001) Genomics of Mycobacterium bovis. Tuberculosis (Edinb) 81: 157-163.
70. Pym AS, Brodin P, Brosch R, Huerre M, and Cole ST (2002) Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46: 709-717.
71. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D, (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37: 88-99.
72. Hsu T, Hingley-Wilson SM, Chen M, Dai AZ, Morin PM, Marks CB, Padiyar J, Goulding C, Gingery M, Eisemberg D, Russell RG, Derrick SC, Collins FM, Morris SL, King CH, Jacobs WR, Jr (2003) The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci USA 100: 12420-12425.
73. Frigui W, Bottai D, Majlessi L, Monot M, Josselin E, Brodin P, Garnier T, Gicquel B, Martin C, Leclerc C, Cole ST, Brosch R (2008) Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog 4: e33.
74. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, and Martin C (2001) An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 41: 179-187.
75. Gonzalo AJ, Maia C, Ferrer NL, Barilone N, Laval F, Soto CY, Winter N, Daffe M, Gicquel B, Martin C, Jackson M (2006) The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem 281: 1313-1316.
76. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, Huygen K, Hernandez-Pando R, Thole J, Behr M, Gicquel B, and Martin C (2008). PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS ONE 3: e3496.
77. Cardona PJ, Asensio JG, Arbues A, Otal I, Lafoz C, Gil O, Caceres N, Ausina V, Gicquel B, and Martin C (2009) Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine 27: 2499-2505.
78. Siegrist MS, Unnikrishnan M, McConnell MJ, Borowsky M, Cheng TY, Siddiqi N, Fortune SM, Moody DB, and Rubin EJ (2009) Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci USA 106: 18792-18797.
79. Serafini A, Boldrin F, Palu G, and Manganelli R (2009) Characterization of a Mycobacterium tuberculosis ESX-3 conditional mutant: essentiality and rescue by iron and zinc. J Bacteriol 191: 6340-6344.
80. Maciag A, Dainese E, Rodriguez GM, Milano A, Provvedi R, Pasca MR, Smith I, Palu G, Riccardi G, and Manganelli R (2007) Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon. J Bacteriol 189: 730-740.
81. Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, Henao-Tamayo M, Ordway D, Sellers RS, Jain P, Chen B, Chen M, Kim J, Lukose R, Chan J, Orme IM, Porcelli SA, Jacobs WR, Jr (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 17: 1261-1268.
82. Abdallah AM, Savage ND, Van ZM, Wilson L, Vandenbroucke-Grauls CM, van der Wel NN, Ottenhoff TH, and Bitter W (2008) The ESX-5 secretion system of Mycobacterium marinum modulates the macrophage response. J Immunol 181: 7166-7175.
83. Sayes F, Sun L, Di Luca M, Simeone R, Degaiffier N, Fiette L, Esin S, Brosch R, Bottai D, Leclerc C, Majlessi L (2012) Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion: encoded PE-PPE proteins predicts vaccine potential. Cell Host Microbe 11: 352-363.
84. Rodrigue S, Provvedi R, Jacques PE, Gaudreau L, and Manganelli R (2006) The sigma factors of Mycobacterium tuberculosis. FEMS Microbiol Rev 30: 926-941.
85. Manganelli R, Voskuil MI, Schoolnik GK, and Smith I (2001) The Mycobacterium tuberculosis ECF sigma factor sigmaE: role in global gene expression and survival in macrophages. Mol Microbiol 41: 423-437.
86. Manganelli R, Provvedi R, Rodrigue S, Beaucher J, Gaudreau L, and Smith I (2004) Sigma factors and global gene regulation in Mycobacterium tuberculosis. J Bacteriol 186: 895-902.
87. Hernandez PR, Aguilar LD, Smith I, and Manganelli R (2010) Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect Immun 78: 3168-3176.
88. Brennan MJ and Delogu G (2002). The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol 10: 246-249.
89. Strong M, Sawaya MR, Wang S, Phillips M, Cascio D, and Eisenberg D (2006) Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103: 8060-8065.
90. Adindla S and Guruprasad L (2003) Sequence analysis corresponding to the PPE and PE proteins in Mycobacterium tuberculosis and other genomes. J Biosci 28: 169-179.
91. Daleke MH, Cascioferro A, de Punder K, Ummels R, Abdallah AM, van der WN, Peters PJ, Luirink J, Manganelli R, and Bitter W (2011) Conserved PE and PPE protein domains target LipY lipases of pathogenic mycobacteria to the cell surface via ESX-5. J Biol Chem 286: 19024-19034
92. Mishra KC, De CC, Narayana Y, Bifani P, Brown AK, Besra GS, Katoch VM, Joshi B, Balaji KN, and Kremer L (2008) Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY. Infect Immun 76: 127-140.
93. Brennan MJ, Delogu G, Chen Y, Bardarov S, Kriakov J, Alavi M, and Jacobs WR, Jr (2001) Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells. Infect Immun 69: 7326-7333.
94. Banu S, Honore N, Saint-Joanis B, Philpott D, Prevost MC, and Cole ST (2002) Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol Microbiol 44: 9-19.
95. Delogu G, Pusceddu C, Bua A, Fadda G, Brennan MJ, and Zanetti S (2004) Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure. Mol Microbiol 52: 725-733.
96. Cascioferro A, Delogu G, Colone M, Sali M, Stringaro A, Arancia G, Fadda G, Palu G, and Manganelli R (2007) PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall. Mol Microbiol 66: 1536-1547.
97. Hoffmann C, Leis A, Niederweis M, Plitzko JM, and Engelhardt H (2008) Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci USA 105: 3963-3967.
98. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, and Daffe M (2008) Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol 190: 5672-5680.
99. Sali M, Di Sante G, Cascioferro A, Zumbo A, Nicolo C, Dona V, Rocca S, Procoli A, Morandi M, Ria F, Palù G, Fadda G, Manganelli R, Delogu G (2010) Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun 78: 5202-5213.
100. Andersen P and Doherty TM (2005) The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.